Search
Please choose your country
more info

Contact:
Phone:+49 0761 1514 440 Fax:+49 0761 1514 460 Email: info@falkfoundation.org

Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Edition 3/2026

Edition 2/2026

Edition 1/2026

Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

All articles

Liver and Bile

Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma

Gut. 2024;74(1):90-102

Chen A, Zhang VX, Zhang Q, Sze KMF, Tian L, Huang H, Wang X, Lee E, Lu J, Lyu X, Lee MFJ, Wong CM, Ho DW, Ng IOL

Liver and Bile

HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States

Hepatology. 2025;81(2):465-475

El-Serag HB, Jin Q, Tayob N, Salem E, Luster M, Alsarraj A, Khaderi S, Singal AG, Marrero JA, Asrani SK, Kanwal F

Liver and Bile

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): A multicentre, randomised, double-blind, phase 3 study

Lancet. 2025;405(10474):203-215

Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM; LEAP-012 investigators

Liver and Bile

A phase 3 biomarker validation of GALAD for the detection of hepatocellular carcinoma in cirrhosis

Gastroenterology. 2025;168(2):316-326.e6

Marsh TL, Parikh ND, Roberts LR, Schwartz ME, Nguyen MH, Befeler A, Page-Lester S, Tayob N, Srivastava S, Rinaudo JA, Singal AG, Reddy KR, Marrero JA

Liver and Bile

Spatial single-cell profiling and neighbourhood analysis reveal the determinants of immune architecture connected to checkpoint inhibitor therapy outcome in hepatocellular carcinoma

Gut. 2025;74(3):451-466

With expert opinion

Salié H, Wischer L, D’Alessio A, Godbole I, Suo Y, Otto-Mora P, Beck J, Neumann O, Stenzinger A, Schirmacher P, Fulgenzi CAM, Blaumeiser A, Boerries M, Roehlen N, Schultheiß M, Hofmann M, Thimme R, Pinato DJ, Longerich T, Bengsch B

Liver and Bile

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): A multiregional, randomised, double-blind, placebo-controlled, phase 3 study

Lancet. 2025;405(10474):216-232

Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Żotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators

Liver and Bile

Assessment of liver graft quality during hypothermic oxygenated perfusion: The first international validation study

J Hepatol. 2025;82(3):523-534

Eden J, Thorne AM, Bodewes SB, Patrono D, Roggio D, Breuer E, Lonati C, Dondossola D, Panayotova G, Boteon APCS, Walsh D, Carvalho MF, Schurink IJ, Ansari F, Kollmann D, Germinario G, Rivas Garrido EA, Benitez J, Rebolledo R, Cescon M, Ravaioli M, Berlakovich GA, De Jonge J, Uluk D, Lurje I, Lurje G, Boteon YL, Guarrera JV, Romagnoli R, Galkin A, Meierhofer D, Porte RJ, Clavien PA, Schlegel A, de Meijer VE, Dutkowski P

Liver and Bile

Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study

J Hepatol. 2025;82(3):512-522

With expert opinion

Tabrizian P, Holzner ML, Ajmera V, Kim AK, Zhou K, Schnickel GT, Torosian K, Hoteit M, Marino R, Li M, Yao F, Florman SS, Schwartz ME, Mehta N

Liver and Bile

Utility of methylated DNA markers for the diagnosis of malignant biliary strictures

Hepatology. 2025;81(2):453-464

Cooley MA, Schneider AR, Barr Fritcher EG, Milosevic D, Levy MJ, Bridgeman AR, Martin JA, Petersen BT, Abu Dayyeh BK, Storm AC, Law RJ, Vargas EJ, Garimella V, Zemla T, Jenkins SM, Yin J, Gores GJ, Roberts LR, Kipp BR, Chandrasekhara V